Long‐term follow‐up of Langerhans cell histiocytosis: 39 years’ experience at a single centre

Authors:

Abstract
Aim: To evaluate the long‐term outcome of Langerhans cell histiocytosis (LCH) in children. Methods: We re‐evaluated all children (Results: Altogether, 5/49 (10%) children died, all with multi‐system disease and age p=0.001) and survival (p=0.014) for the 22 children with multi‐system disease was significantly lower compared with the 27 children with single‐system disease. The term “maximal extent of disease” was introduced since reactivation of LCH often tends to involve additional organs not previously affected by the disease. At follow‐up, late sequelae had developed in 17/40 (42%) patients, including diabetes insipidus in 6/40 (15%), CNS complications in at least 4/40 (10%) (3/16, 19%, of multi‐system patients) and late‐stage pulmonary disease in 4/38 (11%). Seven out of 21 (33%) of the patients with multi‐system disease were alive and healthy without sequelae at follow‐up, as compared to 16/24 (67%) of those with single‐system disease (p=0.026). Of 14 individuals 25 y at follow‐up, senior high school had been completed in 7/9 (78%) with single‐system and 1/5 (20%) with multi‐system disease (at maximal disease extent) (p=0.091). Conclusion: Multi‐system LCH is associated not only with increased mortality but also pronounced propensity for severe late sequelae; 51% of the patients (multi‐system=33%, single‐system=67%) were alive without sequelae at follow‐up. Among multi‐system patients, at least 19% suffered CNS sequelae.

This publication has 27 references indexed in Scilit: